3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Multiple Myeloma
43
Waldenstrom Macroglobulinemia
4
Recurrence
4
Lymphoma, Mantle-Cell
3
Lymphoma
3
Lymphoma, Follicular
2
Leukemia, Myeloid, Acute
2
Smoldering Multiple Myeloma
1
Sarcoma, Kaposi
1
Plasmacytoma
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm, Residual
1
Myelodysplastic Syndromes
1
Lymphoma, T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Plasma Cell
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Erythroblastic, Acute
1
Leukemia
1
Immunoglobulin Light-chain Amyloidosis
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Graft vs Host Disease
1
Genetic Diseases, Inborn
1
Congenital Abnormalities
1
Carcinoma, Renal Cell
1
Interventions
Dexamethasone
7
Cyclophosphamide
4
Bortezomib
4
Melphalan
3
Lenalidomide
3
Calcium Dobesilate
3
pomalidomide
2
Doxycycline
2
ixazomib
1
isatuximab
1
daratumumab
1
birtamimab
1
belantamab mafodotin
1
Vinorelbine
1
Thalidomide
1
Gemcitabine
1
Etoposide
1
Etanercept
1
Doxorubicin
1
Cisplatin
1
Bendamustine Hydrochloride
1
Antineoplastic Protocols
1
ARQ 197
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Amyloidosis
×
ixazomib
×
Clear all
NCT02924272
2025-03-12
Ixazomib Rollover Study
Takeda
Phase 2
Completed
32 enrolled
13 charts